Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Short Interest Update

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) saw a significant increase in short interest in September. As of September 15th, there was short interest totaling 119,360 shares, an increase of 70.3% from the August 31st total of 70,094 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 82,864 shares, the days-to-cover ratio is currently 1.4 days.

Serina Therapeutics Trading Up 3.9%

Shares of SER stock traded up $0.08 during trading hours on Wednesday, reaching $2.09. 2,341 shares of the stock were exchanged, compared to its average volume of 1,574,534. Serina Therapeutics has a 12-month low of $1.22 and a 12-month high of $5.83. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16. The company’s 50-day moving average price is $2.41 and its 200-day moving average price is $2.11. The firm has a market capitalization of $53.06 million, a price-to-earnings ratio of -1.11 and a beta of 1.18.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, BTIG Research restated a “buy” rating and set a $8.00 target price on shares of Serina Therapeutics in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $8.00.

About Serina Therapeutics

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines for chronic diseases. The company uses its proprietary POZ polymer technology to modify therapeutic molecules with the goal of extending their duration of action, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apraglutide, a long-acting version of the peptide apraglutide. The company is evaluating the candidate as a potential treatment for short bowel syndrome with intestinal failure and other conditions in which enhanced intestinal absorption may be beneficial.

The company’s development programs are based on its POZ platform, which is designed to control the release and circulation of attached drug compounds.